Earlier in the week after reading the New York Times reports “U.S. Bet Big on Covid Vaccine Manufacturer Even as Problems Mounted” I commented that “This is a pretty damning report. Especially to the FDA for a failure of their inspection program if even half of it is true.”
Observation 1: Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel
This one is a real bellwether to me. The failure of the quality unit to ensure a robust computer system validation program was in place, to ensure data integrity. The fact that the three parts to the observation run the gamut from infrastructure to implementation to on-going use stands out that there are significant weaknesses in data integrity as an approach.
Observation 2: Established specifications, test procedures and laboratory control mechanisms are not followed and documented at the time of performance.
Part (b) indicates a failure to manage and track lab errors.
Also some concerns on chain of custody of samples are raised.
Observation 3: The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
This observation raises some significant questions in how they manage OOS investigations.
Observation 4: Employees are not given training in the particular operations they perform as part of their function and current good manufacturing practices
Observation 5: Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components before disposition
It is like the FDA saw exactly what was going to happen and did nothing to stop it.
This 483 chilled me to the bones reading it. Major failures in quality here. The fact that this was in April of 2020 raises significant concerns in my mind about how Emergent got any contracts for vaccine delivery.
I have written to my congressional representatives demanding hearings. We need to know who made what decisions when. The trust in our regulatory regime requires full transparency and introspection.